HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ragde, H. Articles by Elgamal, A. A. Search for Related Content PubMed PubMed Citation Articles by Ragde, H. Articles by Elgamal, A. A.

CA: A Cancer Journal for Clinicians, Vol 50, Issue 6 380-393, Copyright © 2000 by American Cancer Society

ARTICLES

Modern prostate brachytherapy

H. Ragde, G. L. Grado, B. Nadir and A. A. Elgamal
Prostate Brachytherapy at Southwest Oncology Center, Scottsdale, AZ, USA.

Of all the treatment options available for men with organ-confined prostate cancer, brachytherapy--permament implantation of radioactive seeds into the prostate gland--is the least disruptive for the patient, both physiologically and practically. Early brachytherapy represents the oldest technique for delivering radiation to the prostate gland, preceding external beam therapy of the prostate by several decades. Although there have not been, and are not likely to be, any definitive randomized studies comparing radical prostatectomy, external beam radiotherapy, and brachytherapy, treatment decisions will continue to be made on the basis of patient and physician preferences in conjunction with clinical probabilities. Long-term results in this series show that monotherapy with seed implants achieved disease-free survival of 66%; moreover, 79% of patients with higher grade disease who were treated with a combination of brachytherapy and external beam radiation also experienced long-term disease-free survival. The following article provides a brief historical review of prostate brachytherapy, rationale for treatments, patient selection criteria, up-to-date implant techniques, and long-term (12-year) outcome results.

This article has been cited by other articles:

				C. K. Gwede and R. J. McDermott Prostate Cancer Screening Decision Making Under Controversy: Implications for Health Promotion Practice Health Promot Pract, January 1, 2006; 7(1): 134 - 146. [Abstract] [PDF]

				C. A. Carter, T. Donahue, L. Sun, H. Wu, D. G. McLeod, C. Amling, R. Lance, J. Foley, W. Sexton, L. Kusuda, et al. Temporarily Deferred Therapy (watchful waiting) for Men Younger Than 70 Years and With Low-Risk Localized Prostate Cancer in the Prostate-Specific Antigen Era J. Clin. Oncol., November 1, 2003; 21(21): 4001 - 4008. [Abstract] [Full Text] [PDF]

				R. C. Susil, A. Krieger, J. A. Derbyshire, A. Tanacs, L. L. Whitcomb, G. Fichtinger, and E. Atalar System for MR Image-guided Prostate Interventions: Canine Study Radiology, September 1, 2003; 228(3): 886 - 894. [Abstract] [Full Text] [PDF]